


END

TB



FEB 26-MAR 01
2025

29th Annual Conference of
The Union-North America Region
Sheraton Wall Centre Hotel, Vancouver, BC



VANCOUVER

On Canada's West Coast, nestled between the rugged Coastal Mountains and the Pacific Ocean, you'll find a city that wows everyone – Vancouver. With a rare blend of cosmopolitan amenities, natural splendours and cultural attractions, our city is truly one of a kind. Vancouver enjoys a rich cultural and ethnic diversity that permeates everything from cuisine and entertainment, to neighbourhoods and traditions. World renowned for our spectacular nature and scenery, you can immerse yourself in the energy of the city yet minutes later enjoy the tranquility of a mountaintop lake. There is no easy way to describe Vancouver. You'll just have to see for yourself.

The best time to visit Vancouver is anytime. Vancouver is green year-round, with the mildest climate in Canada. So no matter what season you choose, you'll never run out of activities.

Stroll through an ancient rainforest, ski the local mountains, shop in trendy districts, explore the city, dine in neighbourhoods, enjoy the vibrant entertainment scene or take in the fabulous sights. Summer signals the great outdoors. Swim at the beach, mountain bike through endless trails, go ocean kayaking or dance at a street festival – the city is alive with activities. Fall starts our entertainment season with Broadway-style musicals, theatre, opera, ballet, concerts and the symphony. Winter is ski season. 20 minutes from downtown, you can tackle the slopes of three outstanding mountains or dine on top of a mountain and drink in the spectacular views. For the serious skier, North America's top ski resort, Whistler, is a short 90-minute drive from Vancouver. And just a ferry ride away lays the British charm of Victoria. Pick the season, and then plan an active and enjoyable visit.

TABLE OF CONTENTS

2	Continuing Medical Education
3	Messages
4	Program
	Keynote Lectures:
8	George Comstock Lecture
9	Beyond TB Lecture
	Awards:
10	Lifetime Achievement
11	Early Career Investigator
	Travel Grants:
12	North America Region
16	International
17	Committees
18	Faculties 2025
27	Sponsors and Exhibitors

CONTINUING MEDICAL EDUCATION



This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Curry International Tuberculosis Center and the International Union Against Tuberculosis and Lung Disease – The Union-NAR. The Curry International Tuberculosis Center is accredited by the ACCME to provide continuing medical education for physicians and nurses.

The Curry International Tuberculosis Center designates this educational activity for a maximum of **20 AMA PRA Category 1 Credits™**. Physicians should only claim credit commensurate with the extent of their participation in the activity.

The Curry International Tuberculosis Center is approved as a provider of continuing education by the California State Board of Registered Nurses, Provider Number CEP 12308. This educational activity is approved for 20 continuing education hours. Board requirements prevent us from offering CE credit to people who arrive more than 15 minutes after the start of the 2025 End TB Conference or leave the 2025 End TB conference early. Therefore, **partial credit will not be awarded.**

Certificates will be available on the Curry International Tuberculosis Center website approximately twelve weeks after the conclusion of the 2025 End TB Conference to all participants who requested CME or nursing credits on their applications and who successfully completed the 2025 End TB Conference. Successful completion includes attending the entire 2025 End TB Conference, signing in each day, and completing an online evaluation. To view your certificate, you will need to log into the CITC website, go to the training page, and click on “training history.” All CME recipients will be contacted 4-months after the 2025 End TB Conference to assist with long-term evaluation activities.

MESSAGES



Lisa Chen, MD
President, The Union-
North America Region

Tuberculosis knows no borders. Ending the spread and suffering from this malady is our common cause. While we have hit a period of uncertainty, we can still join together to take heart that our community of public health providers, scientists, TB survivors and supportive partners can share new findings and insights that will make our work stronger. The NAR family welcomes all to our 29th Annual Conference in beautiful Vancouver! With great appreciation and anticipation – warmest regards!



Rachel Dwilow, MD
2025 Program Chair/
Vice-President, The Union-
North America Region

Welcome to Vancouver, British Columbia for the 29th Annual Conference of the Union- North American Region. Over the last ten months our volunteer conference planning committee has enthusiastically picked a list of topics and assembled an exciting list of speakers we think you will enjoy. Dr. Bob Horsburgh will be speaking about “The Riddle of TB Drug Resistance” for The George Comstock Lecture. The Beyond TB Lecture will be given by Dr. Denis Nash about the effects of climate change on HIV care, an emerging area of research in infectious diseases. We have continued to focus on creating more opportunities for the participation of TB survivors and early career researchers and colleagues in our conference. Our pre-conference activities include a workshop for TB survivors and a post-graduate course on the application of next-generation sequencing for the clinical and public health management of TB. We look forward to seeing you in Vancouver!

PROGRAM

WEDNESDAY | FEB 26, 2025

10:00-4:00	<i>TB Survivors Meeting</i> (Galiano Room) Chairs: Ms. Kate O'Brien and Ms. Leigh Raithby
1:30-4:50	POSTGRADUATE COURSE (Grand Ballroom) <i>Next-generation Sequencing and TB</i> Chairs: Dr. Simon Grandjean Lapierre, Dr. Melissa Richard-Greenblatt, and Dr. Vincent Escuyer
1:30	Introduction
1:40	<i>From DNA to Diagnosis: A Primer on Mycobacterium tuberculosis Next-generation Sequencing for Clinicians</i> Dr. Melissa Richard-Greenblatt, The Hospital for Sick Children, Toronto, ON, Canada
2:00	<i>Genotypic Drug Susceptibility Testing (DST)</i> Dr. Melissa Richard-Greenblatt, The Hospital for Sick Children, Toronto, ON, Canada <i>Sequencing-based DST</i> Dr. Vincent Escuyer, New York State Department of Health, Albany, NY, USA
2:40	Break/Q&A
3:00	<i>Molecular Typing</i> <i>NGS Typing-Based Transmission Studies</i> Dr. Inna Sekirov, BC Centres for Disease Control, Vancouver, BC, Canada <i>Molecular Typing for Laboratory Contamination</i> Dr. Simon Grandjean Lapierre, University of Montreal, Montreal, QC, Canada
3:40	<i>TB NGS Programmatic Implementation Implementation From The Wet-Lab Perspective</i> Dr. Vincent Escuyer, New York State Department of Health, Albany, NY, USA <i>Implementation from the Public Health Perspective</i> Mr. Joseph Shea, New York State Department of Health, Albany, NY., USA
4:20-4:50	Panel Discussion
5:00-7	NAR EXECUTIVE/NAR COUNCIL MEETING (Port Alberni Room)

THURSDAY | FEB 27, 2025

8:00	<i>Welcoming and Opening Remarks</i> Dr. Lisa Chen, President, The Union-NAR Dr. Rachel Dwilow – 2025 Program Chair/Vice President, The Union-NAR
8:10	<i>Opening Prayer</i> Ms. Syexwaliya Ann Whonnock
8:15	<i>Survivor's Perspective</i> Ms. Donna Dumas and Mr. John Dumas
8:45	THE GEORGE COMSTOCK LECTURE: <i>The Riddle of TB Drug Resistance</i> Dr. Bob Horsburgh, Boston University School of Public Health, Boston, MA, USA
9:45	BREAK
10:00-11:55	SESSION 1: STOP TB Session: <i>Protecting Our Communities: TB Vaccines and Community Engagement!</i> Chairs: Dr. Elizabeth Rea, Dr. Cynthia Tschampl and Dr. Sundari Mase
10:00	Introduction
10:05	<i>Global TB Epidemiology Update</i> Dr. Nimalan Arinaminpathy, World Health Organization, Geneva, Switzerland
10:25	<i>Reason for Hope:</i> <i>An Update on TB Vaccines</i> Dr. David Lewinsohn, Oregon Health & Science University, VA Portland Health Care System, Portland, OR, USA
10:50	<i>Community Engagement Strategies and their Importance in Relevant TB Research</i> Dr. Priya Shete, University of California of San Francisco, SF, CA, USA
11:05	<i>Why CABs are Important but Underutilized in the US</i> Mr. Derrick Mapp, Shanti Project, San Francisco, CA, USA
11:20	<i>Oral Abstract Presentation #1</i> <i>Reach and Effectiveness of a Mobile Tuberculosis Screening Program in Lima, Peru (TB MOVIL)</i> Ms. Lauren Linde, Boston University, Boston, MA, USA

PROGRAM

THURSDAY | FEB 27, 2025

11:30-11:50	Panel Discussion
11:55-1:00	Social Networking (Lunch Provided) - Gulf B/C: Public Health Practice - Finback: Clinical Research - Orca: Pediatrics
1:00-2:00	POSTER SESSION 1 <i>Basic Science, Clinical Cases, Clinical Research, Drug Resistant TB, Pediatrics</i>
2:00-4:30	SESSION 2: Nursing and Allied Health Sponsored Session <i>Beyond the Cure: Holistic TB Care</i> Chairs: Ms. Jessica Harper and Ms. Shawna Whitney
2:00	Introduction
2:05	Canadian TB Social Work Network Supporting Holistic TB Care, from Guidelines to Implementation Ms. Jude McLellan, BC Center for Disease Control, Vancouver, BC, Canada
2:35	Becoming a TB Champion-Community Wellness Worker Mr. Jeremiah Prince, First Nations Health Authority, BC, Canada
3:05	BREAK
3:25	Shining a Light on TB at the End-of-life Dr. Dawn Gross & Ms. Lisa True, RN University of California San Francisco, San Francisco, CA, USA
3:55	Oral Abstract Presentation #2 <i>Neighborhoods in Lima, Peru with Poorer Geographic Access to Health Facilities are Associated with Higher Proportions of Loss-To-Follow-Up from Tuberculosis Treatment</i> Dr. Helen Jenkins, Boston University, Boston, MA, USA
4:05	Panel Discussion
4:25	Conclusion
4:30-5:30	Awards Ceremony (Grand Ballroom)
5:30-7	Reception (Grand Ballroom)

FRIDAY | FEB 28, 2025

8:00-9:30	Challenging Clinical Cases #1 Chairs: Dr. Victoria Cook, Dr. Elizabeth Talbot, Dr. Alfred Lardizabal
9:30-11:00	SESSION 3: Adolescent TB: Pathways to Comprehensive Care Chairs: Dr. Meredith Brooks and Dr. Lisa Armitige
9:30	Introduction
9:35	Survivor's Perspective (virtual) Ms. Fatima Hassan
9:45	Adolescent TB: Care Beyond Pills Dr. Silvia Chiang, RISE TB Clinic, Brown University, Providence, RI, USA
10:10	BREAK
10:25	Oral Abstract Presentation #3 <i>A Systematic Review of Tuberculosis-associated Respiratory Impairment and Disability in Children and Adolescents: Evaluation of Current Literature and Identifying Knowledge Gaps and Priorities</i> Dr. Kamila Romanowski, McGill University, Montreal, QC, Canada
10:35	TB-Associated Respiratory Morbidity; Do not Forget the Adolescents Dr. Marieke van der Zalm, Stellenbosch University, Cape Town, South Africa
11:00	BEYOND TB LECTURE: Estimating the Causal Effects of Extreme Weather Events on HIV Care Outcomes in the leDEA Cohort Collaboration: Study Design and Early Results Dr. Denis Nash, CUNY Graduate School of Public Health and Health Policy, New York, NY, USA
12:00-1:00	Non-CME Industry Sponsored Satellite Symposium: TB Groundhog Day: Can We End It? Dr. L. Masae Kawamura, MD, Executive Board of Directors, Vital Strategies Isdore Chola Shamputa, PhD, University of New Brunswick

PROGRAM

FRIDAY | FEB 28, 2025

1:00-2:00	POSTER SESSION 2 <i>Public Health, TB Diagnostics, TB Epidemiology, TB Transmission</i>
2:00-4:30	SESSION 4: Reframing Directly Observed Treatment Chairs: Dr. Kevin Schwartzman and Dr. E. Jane Carter
2:00	Introduction
2:05	Survivor's Perspective Ms. Nicole Skaggs
2:15	Historical Perspective on DOT Dr. E. Jane Carter, Brown University, Providence, RI, USA
2:35	Adherence and Clinical Outcomes: What Does This Mean for DOTs and DATs Dr. Helen Stagg, London School of Hygiene & Tropical Medicine, London, UK
3:00	BREAK
3:20	TB vs HIV – Treatment Support and Supervision Dr. Amrita Daftary, York University, Toronto, ON, Canada
3:45	DOT, Human Rights, and Ethics Dr. Jonathan Stillo, Wayne State University, Detroit, MI, USA
4:10	Oral Abstract Presentation #4 <i>Rifampin-based Tuberculosis Preventative Treatment Outcomes for People Experiencing Drug-drug Interactions: A Secondary Analysis of Completion, Safety, and Health Care Utilization from the 2r2 Trial.</i> Ms. Nancy Bedingfield, McGill International TB Research Center, Montreal, QC, Canada
4:20-4:45	Panel Discussion
5:00-6:00	STOP TB USA/Canada Meeting -Port McNeil: USA -Port Alberni: Canada

SATURDAY | MAR 01, 2025

7:30-9:00	Challenging Clinical Cases #2 Chairs: Dr. Victoria Cook, Dr. Elizabeth Talbot, Dr. Alfred Lardizabal
9:00-12:00	SESSION 5: What Is Hot in Treatment Differentiation and Individualization Chairs: Dr. Jonathon Campbell, Dr. Simon Grandjean Lapierre, and Dr. Ruvandhi Nathavitharana
9:00	Introduction
9:05	Survivor's Perspective Mr. Himanshu Patel
9:15	2025 ECIA Award Winner <i>The Epidemiology of Pediatric Tuberculosis in High-Burden Settings -- Observations from a South African Birth Cohort</i> Dr. Leonardo Martinez, Boston University School of Public Health, Boston, MA, USA
9:40	Individual Risk Stratification and Predictors of TB Treatment Outcome Dr. Rada Savic, UCSF, San Francisco, CA, USA
10:10	BREAK
10:30	What Is a TB Endotype and How Can This Guide Treatment Decisions? Dr. Andrew DiNardo, Baylor College of Medicine, Houston, TX, USA
11:00	From TSTin3D to TSTin4D: Enhancing Tuberculosis Preventive Treatment Decisions with Risk-Benefit Analyses Dr. Mayara Bastos, University of Manitoba, Winnipeg, MB, Canada
11:30	Oral Abstract Presentation #5 <i>Tongue Swabs Used for Tuberculosis Testing Among Symptomatic, Healthcare Seeking Patients and Household Contacts Within the Report South Africa Consortium</i> Dr. Rachel Wood, University of Washington, Seattle, WA, USA
11:40-11:55	Panel Discussion

PROGRAM

SATURDAY | MAR 01, 2025

11:55-1:00	<i>Annual General Meeting</i>
1:00-3:00	SESSION 6: DR-TB Chairs: Dr. Lisa Chen and Dr. Sarah Brode
1:00	Introduction
1:10	<i>Overview of the Changing Landscape of DR-TB Care Globally</i> Dr. Jennifer Furin, Harvard Medical School, Boston, MA, USA
1:40	<i>Programmatic Implementation of Targeted Next-generation Sequencing. Sharing Experience From Eswatini (Sub Saharan Africa)</i> Dr. Debrah Vambe, TB GAPS Project, Eswatini
2:00	<i>Survivor Perspective on Priorities for DR-TB Care</i> Mr. Tenzin Kunor
2:15	<i>endTB and endTB-Q Clinical Trials: Alternatives for Treating Fluoroquinolone-susceptible and Resistant TB in General and Priority Populations</i> Dr. Carole Mitnick, Harvard Medical School, Boston, MA, USA
2:35	<i>Oral Abstract Presentation #6 Use Of Whole-Genome Sequencing for Epidemiological Reporting and Surveillance of Mycobacterium Tuberculosis Complex in New York</i> Mr. Joseph Shea, New York Department of Health, Albany, NY, USA
2:45	Panel Discussion
3:00-3:15	<i>Closing</i>
3:30-4:30	<i>Post-conference meeting</i> (Junior Ballroom C, D)

KEYNOTE LECTURES

GEORGE COMSTOCK LECTURE

The George Comstock Lecture acknowledges Dr. Comstock's pioneering work and leadership over many decades. His direct and personal involvement in advanced research of tuberculosis spanned the period of early BCG trials to the modern era of molecular biology. His steadfast advocacy and tremendous depth of wisdom solidly based on experience was a guiding force for all health workers in the various fields of tuberculosis research all around the world, not only in the United States. His mentorship led us to many fruitful investments in research in tuberculosis prevention. This year's George Comstock Lecture is presented by Dr. Charles R Horsburgh.



C. Robert
Horsburgh, MD

Dr. C. Robert Horsburgh, Jr. is a Professor of Epidemiology, Biostatistics, Global Health and Medicine at Boston University. He is an experienced TB clinician whose research has focused on TB epidemiology and clinical trials. He is currently Co-Chairman of the Union's DR-TB Working Group and Chairman of the Steering Committee of RESIST-TB, an international organization that advocates for improved treatment for persons with Drug-resistant TB.

BEYOND TB LECTURE

When The Union was founded in 1920, the organizers rallied around the dream of eliminating tuberculosis as a public health threat. Since that time, we have seen the development and implementation of the DOTS strategy, the identification of linkages between socioeconomic status and TB, and the introduction of new technologies. Yet, TB remains a global threat. The Beyond TB Lecture of The Union-NAR conference serves to focus attention on forces outside the traditional TB world, assisting us to look beyond the usual partners, usual paths, and usual solutions to innovation and novel public health strategies to achieve our goal. This year's Beyond TB Lecture will be presented by Dr. Denis Nash.



Denis Nash, PhD, MPH

Dr. Denis Nash is a Distinguished Professor of Epidemiology at the City University of New York (CUNY) Graduate School of Public Health & Health Policy. Professor Nash is the founding executive director of the CUNY Institute for Implementation Science in Population Health. He is also co-PI of the Central African Region of the International epidemiology Databases to Evaluate AIDS (IeDEA) and the Associate Director of the NIH-funded Einstein, Rockefeller, CUNY Center for AIDS Research (CFAR).

LIFETIME ACHIEVEMENT



William J.
Burman, MD

Dr. Burman is an infectious diseases and public health doctor working in clinical care (TB and HIV) and TB research. He was in the leadership of the Tuberculosis Trials Consortium (TBTC) for many years, serving as the first chair of the science planning committee. In that role, he worked to expand TBTC capabilities to do a range of high-quality clinical trials, through working groups like the Pharmacokinetics Working Group and the Pediatrics Working Group. His other focus as science planning committee chair was to develop strong working relationships with other clinical trials groups, particularly the NIH-funded HIV clinical trials groups, ACTG and IMPACT. These relationships expanded the reach of the TBTC through large collaborative clinical trials such as the PREVENT-TB trial (3HP) and Study 31 (4 months of moxifloxacin-rifapentine based therapy). During this same time period, he was an investigator in HIV clinical trials through the CPCRA/INSIGHT network. That experience was very valuable in many ways, but particularly in having the chance to see first-hand how the involvement of the community (activists, survivors) at every level improves clinical trials.

In 2011 he stepped back from TB research and became Director of Denver Public Health. It was an exciting and sometimes uncomfortable dive into the deep end of the pool, and he had the chance to get involved and learn about a wide range of public health issues, from childhood obesity to tobacco cessation to COVID. The skills he learned in TB and clinical trials translated quite well to this work – building collaborations with organizations and individuals, getting good data, and involving the community. At the end of 2021 he retired from his full-time position, and it was a pleasure to return to part-time clinical work in HIV and TB care and TB research. With more time to

read and think, he returned to one of the unpublished findings of his first research project as an ID fellow – a retrospective cohort study of a decade of TB in Denver. During that review he had been struck by the frequency of side effects during TB treatment and the serious impact of those side effects on patients and treatment outcomes. He has been lucky to work with great colleagues around the world on these issues since then; the goal is to improve treatment outcomes through improving the patient’s experience of TB treatment.

EARLY CAREER INVESTIGATOR



Leonardo
Martinez, PhD

Dr. Martinez is an Assistant Professor in the Department of Epidemiology at Boston University School of Public Health. His research focuses on tuberculosis epidemiology, particularly in high-risk, vulnerable populations such as children, incarcerated individuals, and people with immunosuppression. Dr. Martinez’s work spans multiple continents, attempting to integrate advanced epidemiological methods with large-scale longitudinal cohorts. His expertise includes the evaluation of interventions such as close contact tracing and mass screening strategies, as well as understanding the impact of co-morbidities like HIV and diabetes on TB risk and outcomes. He is the recipient of several prestigious Union awards, including the Stephen Lawn TB-HIV Research Leadership Prize and the Union Young Investigator Prize. With over 130 publications, including 50 as first or senior author, Dr. Martinez is a leading voice in global tuberculosis research and prevention, actively contributing to international guidelines from the World Health Organization and Pan American Health Organization, as well as collaborative efforts on tuberculosis vaccines and preventive treatment.

TRAVEL GRANTS

NORTH AMERICA REGION



Lauren Linde

Lauren Linde is a PhD student in Epidemiology at the Boston University School of Public Health. She completed a Master of Public Health and Master of City Planning at the University of California, Berkeley, specializing in epidemiology and environmental planning. Her research interests include the epidemiology of infectious respiratory diseases, and particularly intersections between air pollution, climate change, and infectious respiratory disease burden.



Mahder Tracy

Mahder Tracy is a second-year MPH candidate at the UTSW Peter O'Donnell School of Public Health, concentrating on quantitative data science. She received a B.S. in Health Promotion and Disease Prevention from the University of Southern California. As a Graduate Research Assistant in the Omer Research Group, she focuses on statistical analysis and manuscript writing for infectious disease epidemiology and vaccine research.



Lydia Carlson

Lydia Carlson is a Research Project Manager in the Clinical Addiction Research and Education (CARE) Unit at Boston Medical Center. She received her MPH with certificates in Epidemiology and Biostatistics and Global Health Program Design, Monitoring, and Evaluation from Boston University School of Public Health in 2022. Currently, her work supports two studies in Uganda examining the impact of alcohol use on post-TB lung disease among people with HIV.

TRAVEL GRANTS



Anish Madan

Anish Madan is a public health student at Boston University. With a background in pharmaceutical sciences, he is passionate about biostatistics, epidemiology and health economics. He is currently focusing on tuberculosis treatment outcomes and healthcare access. His experience includes working with healthcare datasets to analyze trends, generate insights, and communicate findings. He is eager to explore how data-driven approaches can enhance disease care, improve patient outcomes, and inform policy decisions.



Michaela Barry

Michaela Barry is a PGY-4 Infectious Disease/Addiction Medicine fellow at Boston Medical Center. Her primary clinical and research interests are focused on health equity in infectious disease and improving health outcomes for patients with injection drug use.



Sarah Weber

Sarah is a doctoral student in Epidemiology at Boston University School of Public Health with over five years of experience in tuberculosis research. Her current research explores the intersection of tuberculosis and mental health, with a particular focus on depression and PTSD. Previously, she managed multiple TB cohort studies in South Africa.

TRAVEL GRANTS



Tyler Agbayani

Tyler Agbayani was born and raised on the island of Oahu, Hawaii. He proudly serves his community as the epidemiological specialist for the Hawaii State Department of Health Tuberculosis Branch. He recently earned this position after successfully completing a Master of Public Health degree, specializing in Epidemiology at the University of Hawaii at Manoa. He is passionate about contributing to impactful research and deciphering data to improve public health action.



Dana Chatila

Dana Chatila is currently pursuing a Master of Public Health degree at the University of Illinois Chicago (UIC) with a focus on Epidemiology and Biostatistics, as well as a certificate in Global Health. She is actively involved in diverse research projects, including studies on harm reduction, HIV ART adherence, and active case finding for tuberculosis among pregnant women. With a strong passion for addressing global health challenges, Dana is dedicated to advancing public health knowledge and contributing to evidence-based interventions that improve health outcomes.



Javier Cattle

Javier Cattle is a research data analyst in the Center for Tuberculosis at the University of California, San Francisco. He completed both his undergraduate degree in biological sciences and master's degree in public health with a focus on infectious disease epidemiology at Columbia University. His work focuses on using electronic medical record data to understand patient barriers and health system wide barriers to quality TB care among at risk populations in the United States.

TRAVEL GRANTS



Gabrielle May

Gabrielle May has served as a tuberculosis nurse for the Johnson County Department of Health and Environment for over 10 years. She has been a Registered Nurse since 2012. She earned a Bachelor of Science in Nursing from MidAmerica Nazarene University and is currently working for a Master of Public Health from Kansas State University.



Evelyn Lepka
de Lima

Evelyn Lepka is a physician specializing in infectious diseases from Brazil, with experience in HIV/AIDS, HIV-TB coinfection, and severe TB, as well as managing the toxicity and complications of tuberculosis treatment. She is pursuing a Master of Public Health at Johns Hopkins University, focusing on tuberculosis recurrence in Brazil.

INTERNATIONAL



Beatriz Ferro Ramos

Dr. Beatriz E. Ferro Ramos, a microbiologist and infectious disease researcher, who specializes in tuberculosis and nontuberculous mycobacteria. She holds a PhD in Medical Sciences from Radboud University and her research focuses on innovative treatments and diagnostics for bacterial diseases. As an Associate Professor at Universidad Icesi, Cali, she leads an undergrad program, mentors students, and performs multidisciplinary research that contributes to public health. Fluent in English and Spanish, she champions collaborative, impactful research.



Isabelle Nisida

Dr. Isabelle Nisida is an Assistant Professor and postdoctoral researcher in the Infectious Disease Division at the University of São Paulo Medical School (HCFMUSP). Since 2012, she has been at the forefront of research on breast tuberculosis, working with over 500 patients. Dr. Nisida has pioneered an innovative approach to identifying extrapulmonary tuberculosis patients through social media, creating a robust community of 1,500 individuals who offer mutual support. She provides both in-person and online treatment for women across Brazil and internationally.

COMMITTEES

NAR Executive Committee

President: Lisa Chen, MD,
University of California San
Francisco, San Francisco, CA, USA

Vice-President/2025 Program

Chair: Rachel Dwilow, MD,
University of Manitoba, Winnipeg,
MB, Canada

Secretary/Treasurer:

Karen Jacobson, MD, Boston
University School of Medicine,
Boston, MA, USA

President-Elect: James Johnston, MD,
BC Centre for Disease Control,
Vancouver, BC, Canada

Immediate Past Vice-President:

Jonathan Golub, PhD, MPH,
Johns Hopkins University School of
Medicine Baltimore, MD, USA

Immediate Past President: Kevin
Schwartzman, MD, MPH, McGill
University, Montreal, QC, Canada

Secretariat: Menn Biagtan, MD,
MPH, British Columbia Lung
Foundation, Vancouver, BC,
Canada

Ex-Officio: Christopher Lam,
British Columbia Lung Foundation,
Vancouver, BC, Canada

2025 Planning Committee

Lisa Armitige, MD, PhD,
Heartland National TB Center,
San Antonio, TX, USA

Carolyn Bargman, RN,
Denver, CO, USA

Menn Biagtan, MD, MPH,
British Columbia Lung Association,
Vancouver, BC, Canada

Sarah Brode, MD,
Westpark Healthcare Center,
Toronto, ON, Canada

Meredith Brooks, PHD, MPH,
Boston University School of Public
Health, Boston, MA, USA

Jonathon Campbell, PHD, McGill
University, Montreal, QC, Canada

E. Jane Carter, MD,
Brown University,
Providence, RI, USA

Lisa Chen, MD,
University of California San
Francisco, San Francisco, CA, USA

Victoria Cook, MD,
BC Centre for Disease Control,
Vancouver, BC, Canada

Rachel Dwilow, MD (Chair)
University of Manitoba,
Winnipeg, MB, Canada

Vincent Escuyer, MD
New York Department of
Health, Albany, NY, USA

Jonathan Golub, PhD, MPH,
Johns Hopkins University School of
Medicine Baltimore, MD, USA

Melissa Richard-Greenblatt, PHD,
Hospital for Sick Children, Toronto,
ON, Canada

Jessica Harper, RN,
BC Centre for Disease Control,
Vancouver, BC, Canada

C. Robert Horsburgh, MD,
Boston University School of Public
Health, Boston, MA, USA

Karen Jacobson, MD,
Boston University School of
Medicine, Boston, MA, USA

Rehanna Khan, RN,
Toronto Public Health,
Toronto, ON, Canada

Ian Kitai, MD,
Hospital for Sick Children,
Toronto, ON, Canada

Simon Grandjean-Lapierre, MD
University of Montreal,
Montreal, QC, Canada

Alfred Lardizabal, MD,
NJMS Global Tuberculosis, Institute
at Rutgers, Newark, NJ, USA

Joan Mangan, PhD, MPH
Centers for Disease Control and
Prevention, Atlanta, GA, USA

Sundari Mase, MD,
Department of Health Services,
Santa Rosa, CA, USA

Kelly Musoke, MPH,
University of California San
Francisco, San Francisco, CA, USA

Ruvandhi Nathavitharana, MD,
Beth Israel Deaconess Medical
Center, Boston, MA, USA

Elizabeth Rea, MD,
Toronto Public Health, Toronto,
ON, Canada

Kevin Schwartzman, MD, MPH,
McGill University,
Montreal, QC, Canada

Priya Shete, MD,
University of California San
Francisco, San Francisco, CA, USA

Elizabeth Talbot, MD,
Geisel School of Medicine at
Dartmouth, Hanover, NH, USA

Cynthia Tschampl, PhD,
Brandeis University, Waltham,
MA, USA

Shawna Whitney, RN, MPH,
First Nations Health Authority,
Westbank, BC, Canada

Isa Wolf, RN,
TB Program Saskatoon, SK, Canada

Abstract Committee

Lisa Armitige, MD
John Bernardo, MD
Tara Bouton, MD
Sarah Brode, MD
Meredith Brooks, MD
Jeffrey Campbell, MD
Jonathon Campbell, MD
E. Jane Carter, MD
William Connors, MD
Victoria Cook, MD
Ryan Cooper, MD
Katelyne Gardner Toren
Jonathan Golub, PhD, MPH
Akshay Gupte, MD
Jennifer Guthrie, PhD
Connie Haley, MD
Peri, Hopkins, MD
C. Bob Horsburgh Jr, MD
Pat Iyer, MD
John Jereb, MD
Ian Kitai, MD
Joan Mangan, PhD
Leo Martinez, PhD
Sonal Munsiff, KD
E. Ann Misch, MD
Caitlin Reed, MD
Laura Romo-Timme, MD
Zulma Rueda, MD
Nadya Sabuwala
Sheela Sheno, MD
Elizabeth Talbot, MD
Cynthia, Tschampl, PhD
Shu -Hua Wang, MD

FEB 26 | POST GRADUATE COURSE



Vincent Escuyer, PhD

Vincent Escuyer is the Director of Mycobacteriology at Wadsworth Center, the New York State Public Health laboratory. He is also the laboratory consultant for the Global Tuberculosis Institute, one of the National Tuberculosis Centers of Excellence supported by CDC that provides training, education, and medical consultation to healthcare professionals.

His main interest resides in rapid diagnostic and detection of drug resistance, using phenotypic and molecular methods including whole genome sequencing and targeted next-generation sequencing.



Melissa Richard-Greenblatt, PhD

Melissa Richard-Greenblatt received her PhD at the University of British Columbia in the area of tuberculosis and completed her Clinical Microbiology Fellowship at the University of Pennsylvania. For several years, she was head of the mycobacteriology laboratory at Public Health Ontario before transitioning to her current position as a Clinical Microbiologist at SickKids where she continues a research program in tuberculosis. Dr. Greenblatt is an Assistant Professor at the University of Toronto in the Department of Laboratory Medicine and Pathobiology.



Simon Grandjean Lapierre, MD

Simon Grandjean Lapierre is an Associate Professor of Microbiology at the Université de Montréal. His research focuses on the impact of TB molecular typing on disease control and AI-assisted acoustics analyses for TB screening and treatment monitoring.

2025 FACULTIES



Inna Sekirov, MD

Dr. Inna Sekirov is a Medical Microbiologist at the BCCDC Public Health Laboratory and holds a Clinical Assistant Professor appointment with the UBC Department of Pathology and Laboratory Medicine. Over the course of the COVID-19 pandemic she has become involved in a variety of SARS-CoV-2 serology-related projects, including serosurveillance initiatives. Serological approaches and their utility for public health and clinical diagnostics continue to hold a special place in her heart.



Joseph Shea, MS

Mr. Joseph Shea is a microbiologist in the Mycobacteriology Laboratory at the Wadsworth Center, New York State Department of Health. After working in a food manufacturing lab, Joseph began working with tuberculosis while completing a master's degree in lab sciences to pursue a career in public health. His research interests include antimicrobial resistance and molecular epidemiology of *M. tuberculosis* complex and zoonotic tuberculosis.

2025 FACULTIES

FEB 27 | STOP TB SESSION



Nimalan
Arinaminpathy, MD

Dr. Nim Arinaminpathy is Team Lead in TB Monitoring, Evaluation and Strategic Information in the WHO Global TB Programme, Geneva. He leads development of methods to estimate the global burden of tuberculosis, and also performs capacity building in mathematical and statistical modelling. His background is in mathematical epidemiology; he also provides technical assistance for countries, in modelling the impact and cost-effectiveness of interventions against TB.



Priya Shete, MD

Dr. Shete is an Associate Professor in Residence in the Departments of Medicine and Epidemiology and Director of the Clinical and Population Health Sciences Core at the UCSF Center for TB. She also directs an Implementation Science Training Program. Dr. Shete combines methods in implementation science and health policy to design, evaluate, and integrate context appropriate person-centered interventions that reduce both socioeconomic and health impacts of TB on marginalized populations. Dr. Shete is a practicing Pulmonary and Critical Care Physician at San Francisco General Hospital.



Derrick Mapp

Derrick Mapp is currently the Senior Services Care Navigator and Health Counselor at the Shanti Project, San Francisco. He is a dedicated community advocate in HIV, cancer, BIPOC and GLBTIA+ communities and is involved with several HIV-related research networks to advocate and represent community interests and concerns in research development. He is also the global community representative of the NIC-funded AIDS Malignancy Consortium (AMC) and UTRAC and a council member of the region's HIV Services Ryan White Council.

2025 FACULTIES



David Lewinsohn,
MD, PhD

David M. Lewinsohn is a Professor at Oregon Health & Sciences University. He received his undergraduate degree from Haverford College, his MD and PhD from Stanford University School of Medicine, internal medicine training at the University of California, San Francisco, and fellowship training in Pulmonary and Critical Care Medicine at the University of Washington.

Dr. Lewinsohn's research interest is in tuberculosis immunology. The core research question has been that of how the immune system can find those cells harboring the intracellular bacterium. He had a long-standing interest in the development of vaccines for

tuberculosis. He participated in the development of the M72/AS01E vaccine and serves as the chair of the Stop TB Partnership Working Group on Vaccines.

2025 FACULTIES

FEB 27 | NURSING & ALLIED HEALTH SPONSORED SESSION



Jude McLellan

Jude McLellan is the TB Clinic Social Worker at the BC Centre for Disease Control. She has a background in healthcare, archaeology, and forensics, as well as Indigenous Child Welfare. Jude is the co-creator and facilitator of the Canadian TB Social Work Network.



Jeremiah Prince

Jeremiah Prince comes from Saikuz First Nation, a small community in northwest British Columbia, of approximately 350 members on-reserve. His community is one of many bands of the Carrier Nation and Jeremiah is from the Frog Clan on his mother's side. He has lived most of his life in the community and has served 2 years in the TB Community wellness worker role. He is also the Recreation Coordinator for his community. He grew up with a single mother, 3 older brothers and has 10 children, which makes family priority. Sports such as baseball, hockey, tennis, golf, and basketball have been important foundations to healthy physical/mental health and wellness. Coaching the youth has been key to connections and keeping relationships thriving.



Lisa True, RN

Lisa True is a senior nurse consultant with the Curry International TB Center based in San Francisco. She previously worked as the MDR TB nurse coordinator for the California TB Control Branch. She has also worked as a hospice nurse and adult day health nurse. She enjoys hiking and birding and recently began writing stories about her experience as a nurse.

2025 FACULTIES

FEB 28 | PEDIATRIC SESSION



Dawn Gross, MD, PhD

Dr. Dawn Gross has dedicated her career to being a hospice and palliative medicine physician that helps in supporting people in discovering what matters most. Highlighted in the TEDx talk “Ask. The Time is Now,” Dawn demonstrates how practicing curiosity is key to informing actions and advocacy that makes it possible for wishes to come true. Medical director of ANX Hospice and part of the UCSF and Zuckerberg San Francisco General Hospital Palliative Care teams, Dawn has partnered with the CDC to support under-resourced community healthcare workers in navigating the waters of end-of-life care unique to the people of the Pacific Islands.



Silvia Chiang, MD

Dr. Silvia Chiang is a pediatric infectious disease physician who conducts research on childhood and adolescent tuberculosis. She attends on the pediatric infectious disease service at Hasbro Children’s and the RISE Tuberculosis Clinic in Providence, Rhode Island.

Most of her research takes place in Peru, in collaboration with Socios En Salud. She also has ongoing collaborations in Ukraine, Brazil, and Argentina. She contributed to the 2022 World Health Organization consolidated guidelines and operational handbook.



Marieke Van Der Zalm, MD

Dr. Marieke Van Der Zalm is a pediatrician and Associate Professor in the Department of Pediatrics and Child Health at Stellenbosch University, South Africa. She has over 10 years of experience working in pediatric TB and leads the TB diagnostic and lung health studies at the Desmond Tutu TB Centre (DTTC). She was the founder and co-chair of the 1st and 2nd International Post TB Symposium, chaired the pediatric working group on both occasions, and will again for the 3rd Symposium. Since 2024, she has also been the co-chair of the International Union Against Tuberculosis and Lung Disease (Union) Post-TB working group.

2025 FACULTIES

FEB 28 | REFRAMING DIRECTLY OBSERVED TREATMENT



Helen Stagg, PhD

Dr. Helen R. Stagg is a tenured Professor of Infectious Disease Epidemiology in the Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine. She began her career in the life sciences, later pivoting into epidemiology, with an extensive track record in working with industry, and national and international policy making/influencing bodies. She has a long-standing interest in adherence to anti-TB treatment, an area in which she held a Medical Research Council, UK, fellowship from 2018-2024.



Amrita Daftary, PhD

Dr. Amrita Daftary is an Associate Professor at the School of Global Health, York University. She researches the social dimensions of TB and TB care, including stigma and inequity, using qualitative approaches. She works alongside trialists and in allyship with TB-affected communities in South Africa, India, Indonesia, Ukraine, and Canada, among other countries, as well as with global decision-makers. She is the founder of a social science network in TB.



Jonathan Stillo, PhD

Dr. Jonathan Stillo is a Medical Anthropologist and Assistant Professor at Wayne State University. He has researched TB for more than twenty years. His research and advocacy focus on the social, economic, and political dimensions of the global tuberculosis crisis. He is the Chair-Elect of STOP TB USA, the Vice-Chair of TB Europe Coalition, and is an emeritus member of the Global TB Community Advisory Board.

MAR 01 | TB SCIENCE



Rada Savic, PhD

Dr. Rada Savic is a Professor at the University of California San Francisco, Program Director of UCSF's Clinical Pharmacology and Therapeutics Fellowship, Co-Vice Dean of Graduate Pharmacy Education Programs, Associate Director of the UCSF Center for TB, and a Chan-Zuckerberg Biohub Investigator. Her research focuses on data integration and the transformative potential of computational tools and artificial intelligence to advance drug development and routine drug therapy in infectious diseases, including special populations such as children and pregnant women. Dr. Savic applies innovative, quantitative and systems pharmacology methods to propose optimized and precision dosing strategies, data-driven risk stratification algorithms, and inspires new clinical simulation tools across the infectious disease landscape.



Andrew DiNardo, MD

Dr. Andrew DiNardo is an infectious disease physician at Baylor College of Medicine. In Houston, he co-leads the Ben Taub General Hospital TB clinic with Dr. Elizabeth Guy. He also spends three months a year in Eswatini studying how the epigenetics of host immunity regulates inflammation, affecting post-tuberculosis cardiovascular disease and post-TB lung damage. Recognizing there is no single uniform immune response to TB, in partnership with Professor Cristian Coarfa, Andrew implemented unbiased bioinformatic analysis to begin to define TB endotypes.



Mayara Bastos, MD, PhD

Dr. Bastos previously trained as an infectious diseases specialist in Brazil and has extensive clinical experience in tuberculosis and related conditions. She is currently a Family Medicine resident at the University of Manitoba. She holds a PhD in Epidemiology and completed a postdoctoral fellowship at McGill University. Her research focuses on scaling up TB preventive treatment, improving diagnosis, advancing MDR-TB management, and addressing post-tuberculosis disability.

2025 FACULTIES

MAR 01 | DR-TB



Jennifer Furin, MD, PhD

Dr. Jennifer Furin is an infectious diseases clinician and medical anthropologist. She has almost 30 years of experience working on TB in multiple global settings. She specializes in the care of people with highly resistant forms of TB, including children, pregnant people/women, and other vulnerable populations. She is currently based at Harvard Medical School in the Department of Global Health and Social Medicine and serves as a program consultant in multiple countries, including Georgia, South Africa, Eswatini, and Burundi. She is also the director of capacity building at the Sentinel Project on Pediatric Drug-Resistant TB.



Carole Mitnick, MD

Dr. Mitnick is Professor of Global Health & Social Medicine at Harvard Medical School (HMS) and Associate Epidemiologist in the Division of Global Health Equity at Brigham & Women's Hospital. She has 25 years of experience in programmatic support, research (observational and experimental), policy, and advocacy related to increased access to high-quality, appropriate treatment for TB, especially for drug-resistant TB. Dr. Mitnick works in close collaboration with Partners In Health, specifically in Peru, Haiti, Kazakhstan, and Lesotho. She supports the HMS Master of Medical Science in Global Health Delivery Program. She is the co-PI of the endTB and endTB-Q trials, two multi-country, Phase III, randomized, controlled, clinical trials of all-oral, shortened, novel regimens for rifampin-resistant TB.



Debrah Vambe, MD

Dr. Debrah Vambe, an accomplished public health professional with 17 years of experience, specializes in TB and HIV. As the Global TB Program Instructor at Baylor College of Medicine, she oversees TB GAPS projects in Eswatini, Lesotho, Malawi, Uganda, and Tanzania. Debrah's expertise in Drug-resistant TB and leadership in international initiatives significantly contribute to health systems strengthening in resource-limited settings, making her a key figure in advancing global TB control efforts.

SPONSORS + EXHIBITORS

SPONSORS:

Pittsfield
Anti-Tuberculosis
Association



PLATINUM SPONSOR:



EXHIBITORS:



**SAVE
THE
DATE**

30th Annual Conference of
the Union - North America Region
2026 END TB CONFERENCE
February 24-28, 2026 | Philadelphia, USA



PHILADELPHIA

The Union

International Union Against
Tuberculosis and Lung Disease



BC LUNG
FOUNDATION